- Home
- BIIB vs SSNC Comparison
BIIB vs SSNC Comparison
Compare BIIB & SSNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- SSNC
- Stock Information
- Founded
- BIIB 1978
- SSNC 1986
- Country
- BIIB United States
- SSNC United States
- Employees
- BIIB N/A
- SSNC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- SSNC EDP Services
- Sector
- BIIB Health Care
- SSNC Technology
- Exchange
- BIIB Nasdaq
- SSNC Nasdaq
- Market Cap
- BIIB 19.9B
- SSNC 19.3B
- IPO Year
- BIIB 1991
- SSNC 1996
- Fundamental
- Price
- BIIB $125.59
- SSNC $79.60
- Analyst Decision
- BIIB Buy
- SSNC Strong Buy
- Analyst Count
- BIIB 27
- SSNC 7
- Target Price
- BIIB $201.26
- SSNC $93.57
- AVG Volume (30 Days)
- BIIB 1.6M
- SSNC 1.7M
- Earning Date
- BIIB 05-01-2025
- SSNC 04-24-2025
- Dividend Yield
- BIIB N/A
- SSNC 1.25%
- EPS Growth
- BIIB 26.39
- SSNC 27.70
- EPS
- BIIB 10.12
- SSNC 3.22
- Revenue
- BIIB $9,816,400,000.00
- SSNC $5,960,900,000.00
- Revenue This Year
- BIIB N/A
- SSNC $7.31
- Revenue Next Year
- BIIB N/A
- SSNC $4.99
- P/E Ratio
- BIIB $12.43
- SSNC $24.77
- Revenue Growth
- BIIB 1.59
- SSNC 6.92
- 52 Week Low
- BIIB $110.04
- SSNC $60.01
- 52 Week High
- BIIB $238.00
- SSNC $89.73
- Technical
- Relative Strength Index (RSI)
- BIIB 55.21
- SSNC 55.89
- Support Level
- BIIB $119.18
- SSNC $78.49
- Resistance Level
- BIIB $124.82
- SSNC $80.75
- Average True Range (ATR)
- BIIB 3.81
- SSNC 1.69
- MACD
- BIIB 1.21
- SSNC 0.57
- Stochastic Oscillator
- BIIB 98.29
- SSNC 85.28
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.